|
Thu, 03/31/2022 - 13:07 |
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence |
Seattle Genetics |
|
Fri, 02/04/2022 - 03:15 |
Seagen Appoints Lee Heeson as Executive Vice President, Commercial International |
Seattle Genetics |
|
Thu, 08/20/2020 - 04:21 |
Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer |
Seattle Genetics |
|
Tue, 05/12/2020 - 06:32 |
Seattle Genetics Announces the Approval of TUKYSA (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer |
Seattle Genetics |
|
Mon, 04/20/2020 - 11:36 |
TUKYSA (tucatinib), FDA Approved for Treatment of Advanced Unresectable or Metastatic HER2 Positive Breast Cancer, Available at Biologics by McKesson |
McKesson |
|
Mon, 04/20/2020 - 05:50 |
Seattle Genetics Announces U.S. FDA Approval of TUKYSA (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer |
Seattle Genetics |
|
Fri, 04/17/2020 - 15:46 |
FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer |
FDA |
|
Fri, 04/17/2020 - 00:35 |
Dana-Farber researchers present key studies at ASCO annual meeting |
Dana Farber |
|
Tue, 03/31/2020 - 14:27 |
- Switzerlands First Approval Under FDA Initiative Project Orbis - |
Seattle Genetics |
|
Wed, 03/25/2020 - 07:55 |
ENHERTU Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer |
Daiichi Sankyo |
|
Fri, 01/31/2020 - 05:44 |
EMA Validates Seattle Genetics Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer |
Seattle Genetics |
|
Mon, 12/23/2019 - 11:33 |
- Application Supported by Results of Pivotal HER2CLIMB Trial - |
Seattle Genetics |
|
Wed, 12/11/2019 - 09:48 |
New targeted drugs show promise in patients with advanced HER2-positive breast cancer in two clinical trials |
Dana Farber |
